Welcome to our dedicated page for Acer Therapeutics news (Ticker: ACER), a resource for investors and traders seeking the latest updates and insights on Acer Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acer Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acer Therapeutics's position in the market.
Acer Therapeutics Inc. (Nasdaq: ACER) reported its Q3 2020 financial results, noting a net loss of $5.9 million, or $0.51 per share. Cash and equivalents stood at $6.2 million, down from $12.1 million in 2019. The company is advancing its four drug programs, including ACER-001 for urea cycle disorders, with a pre-NDA meeting with the FDA anticipated in mid-2021. Emetine studies are ongoing to assess safety against COVID-19. They are also preparing for an IND submission for osanetant in Q2 2021. Despite challenges, Acer aims to fund operations into Q1 2021 with additional capital efforts.
Acer Therapeutics Inc. (Nasdaq: ACER) announced a virtual corporate overview for September, 2020, at the LD Micro 500 Virtual Conference and H.C. Wainwright 22nd Annual Global Investment Conference. The LD Micro event is scheduled for September 1, 2020, at 3 p.m. ET, while the H.C. Wainwright conference will occur on September 15, 2020, at 2:30 p.m. ET. Acer focuses on therapies for serious rare diseases, featuring a pipeline that includes options for COVID-19 and various genetic disorders. More details are available on their website.
Acer Therapeutics Inc. (Nasdaq: ACER) reported its Q2 2020 financial results, ending June 30, with a net loss of $5.8 million, or $0.56 per share, a significant improvement over a $11.0 million loss in Q2 2019. The company is advancing two key programs: emetine, a potential COVID-19 treatment, and ACER-001 for Urea Cycle Disorders (UCDs). Emetine is in collaboration with NCATS and aims for a Phase 2/3 trial pending capital. ACER-001 shows promise in fasted dosing, with an NDA expected in early 2021, subject to funding. Acer ended Q2 with $5.9 million in cash.
Acer Therapeutics announced promising findings regarding ACER-001, a taste-masked formulation of sodium phenylbutyrate aimed at treating Urea Cycle Disorders (UCDs). Data from a food effect study indicate that ACER-001, when taken in a fasted state, enhances the drug's effectiveness compared to existing treatments. The company plans to submit the NDA for ACER-001 in H1 2021, contingent on completing further nonclinical work and securing additional capital. CEO Chris Schelling expressed optimism about ACER-001's potential for better patient compliance and outcomes.
Acer Therapeutics Inc. (Nasdaq: ACER) reported its Q1 2020 financial results, ending March 31, with a cash position of $7.0 million, down from $12.1 million in Q4 2019. The company is focusing on advancing its drug pipeline, notably working on emetine for COVID-19 in collaboration with NCATS and preparing for an NDA submission for ACER-001 for urea cycle disorders in early 2021. The net loss narrowed to $4.9 million, or $0.49 per share, from $8.0 million, or $0.79 per share, a year earlier. Despite the challenges, Acer remains optimistic about its future developments.
Acer Therapeutics has entered a collaboration with the National Center for Advancing Translational Sciences to develop emetine hydrochloride as a treatment for COVID-19. The company plans to initiate a Phase 2/3 trial targeting high-risk outpatients in Q3 2020, pending IND submission and funding. The trial will assess emetine's safety and antiviral activity. Acer is pursuing various financing options, including government grants, to support this initiative. CEO Chris Schelling expressed optimism about the collaboration and the potential for advancing clinical development.